Related Experiment Video
Updated: Jan 7, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions
Monica-Daniela Padurariu-Covit1,2, Costinela Georgescu3, Mihaela Andreescu4,5
1Department of Clinical Medicine, Medicine and Pharmacy Faculty, "Dunarea de Jos" University of Galati, 800008 Galati, Romania.
None:
Antiretroviral therapy (ART) effectively suppresses HIV replication but fails to eradicate latent reservoirs, leading to viral rebound after interruption. Chimeric antigen receptor (CAR) T-cell therapy offers a potential strategy to achieve durable remission. A systematic PubMed search (July 2020-June 2025) identified 253 studies on CAR-T therapy in HIV; 74 met inclusion criteria and were qualitatively analyzed. Preclinical data showed that CAR-T cells can recognize and eliminate infected cells, reach viral reservoirs, and persist long term, particularly when derived from hematopoietic stem cells. Dual-target and combination approaches with checkpoint inhibitors or latency-reversing agents enhanced antiviral efficacy. Early clinical studies confirmed safety and modest reservoir reduction. CAR-T cell therapy represents a promising step toward a functional HIV cure. Further optimization of design, integration with gene-editing technologies, and standardized clinical evaluation are required to confirm durable efficacy and safety.
Related Concept Videos
Tumor Immunotherapy
Microorganisms in Medicine and Therapeutics
Retrovirus Life Cycles
Gene Therapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
iPS Cell Differentiation

